The Question at the Heart of Bird Flu Research
Avian influenza viruses circulate constantly in wild bird populations, most of the time causing minimal disease and posing little direct threat to humans or domestic poultry. Periodically, variants emerge that are highly pathogenic—killing large proportions of infected birds, occasionally spilling over into human infections with high fatality rates, and raising the prospect of a pandemic if they acquire efficient human-to-human transmission.
Understanding why some avian influenza variants become highly pathogenic while most do not has been a central question in virology for decades. A new study published in Science by researchers analyzing H5 highly pathogenic avian influenza viruses has identified a specific molecular mechanism—polymerase trapping—that appears to drive the genesis of the highly pathogenic phenotype.
Influenza Polymerase and Viral Replication
Influenza viruses replicate by hijacking the host cell's molecular machinery to copy their RNA genome and produce new viral proteins. Central to this process is the viral RNA-dependent RNA polymerase—a complex of three viral proteins (PA, PB1, and PB2) that copies the viral genome and transcribes it into messenger RNA for protein production.
The polymerase complex must navigate a fundamental tension during replication: it needs to efficiently copy the viral genome while avoiding triggering the cell's innate immune sensors, which detect double-stranded RNA and other replication intermediates as signs of viral infection. Highly pathogenic viruses tend to have polymerase complexes that replicate more efficiently and evade innate immune detection more effectively than their low-pathogenicity counterparts.
The Polymerase Trapping Mechanism
The new research identifies a specific mechanism by which certain mutations in the viral polymerase lead to the highly pathogenic phenotype. In the studied H5 viruses, mutations that generate the multibasic cleavage site—the molecular signature most directly associated with high pathogenicity—also create conditions where the polymerase complex becomes physically trapped during replication.
This trapping alters the dynamics of viral RNA synthesis in ways that paradoxically enhance certain aspects of viral replication. The trapped polymerase generates more short abortive RNA products that serve as ligands for cellular innate immune sensors—but in the context of the mutations present in highly pathogenic strains, this immune stimulation is insufficient to clear the infection and may actually contribute to the severe inflammatory responses associated with highly pathogenic avian influenza in mammals.
The researchers used cryo-electron microscopy imaging of the polymerase complex in trapped and untrapped states, combined with functional virological assays, to connect the molecular mechanism to the observed biological phenotype. This mechanistic detail is important because it identifies a specific and potentially druggable molecular event in the transition from low- to high-pathogenicity influenza.
Implications for Surveillance and Preparedness
The identification of polymerase trapping has practical implications for surveillance. Current surveillance programs monitor circulating avian influenza viruses primarily for the presence of the multibasic cleavage site. The new research suggests that monitoring for the specific polymerase mutations associated with trapping—which may precede or accompany the emergence of the cleavage site—could provide earlier warning of viruses acquiring pandemic potential.
H5N1 avian influenza remains a serious ongoing concern. The current H5N1 clade 2.3.4.4b has caused unprecedented outbreaks in wild birds and mammals across multiple continents over the past three years. Human cases, while relatively rare, have occurred with a historically high fatality rate. The detection of H5N1 in dairy cattle herds in the United States beginning in 2024 raised concerns about mammalian adaptation and potential transmission pathways not previously considered.
Antiviral Development Prospects
The polymerase trapping mechanism represents a potential antiviral target. Drugs that block or alter the polymerase dynamics associated with the trapping state could potentially interfere with the replication advantage that contributes to high pathogenicity. Existing polymerase inhibitors like baloxavir marboxil, which targets the endonuclease domain of the PA polymerase subunit, provide a proof of concept that the influenza polymerase complex is a viable antiviral target.
Whether the specific structural features of the trapping mechanism are accessible to small-molecule inhibitors at therapeutic concentrations will require further research. But the identification of a mechanistically defined molecular event in the pathogenicity transition provides a more specific target than was previously available and may guide antiviral discovery programs over the coming years.
This article is based on reporting by Science (AAAS). Read the original article.
